Filtered By:
Specialty: Hematology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 643 results found since Jan 2013.

Time trends in pulmonary embolism: A matter of age and gender
Venous thromboembolism (VTE) is the third most common cardiovascular disease . Pulmonary embolism (PE) is potentially lethal and is the most serious manifestation of VTE . Notably, PE is the leading preventable cause of death in hospitalized patients , and is the third most common cardiovascular cause of death after myocardial infarction and stroke in Western world . Risk factors for VTE and PE include old age, surgery, immobilization, trauma, fractures, cancer, pregnancy, puerperium, oral contraceptive pill (OCP) use, and hormone replacement therapy (HRT) . Genetic factors are also important in VTE risk and family history...
Source: Thrombosis Research - June 24, 2013 Category: Hematology Authors: Bengt Zöller Tags: Editorials Source Type: research

New anticoagulants
Arterial and venous thromboembolism are a major health problem and a leading preventable cause of morbidity and mortality. Novel – oral – anticoagulants (NOACs) have recently been introduced into the clinical arena after careful evaluation in clinical trials. They constitute a new array of unique, molecular base designed antithrombotic agents with improved pharmacokinetic and pharmacodynamics characteristics. They have the potential of revolutionizing the treatment in our patients but at the same time important practical issues deserve our attention. This volume, written by international experts from Europe as well as ...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: Menno V. Huisman Source Type: research

Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation.
In conclusion, preventing patients with cardiovascular disease from discontinuing ASA could result in substantial clinical and economic gains. PMID: 24008261 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 5, 2013 Category: Hematology Authors: Cea Soriano L, Garcia Rodriguez L, Bueno H, Lanas A Tags: Thromb Haemost Source Type: research

Antithrombotic Medication Use and Bleeding Risk in Medically Ill Patients After Hospitalization
Conclusions: Careful consideration of these demonstrated bleed-associated comorbidities before initiating anticoagulation or combining antithrombotic medications in medically ill patients may improve strategies for prevention of postdischarge thromboembolism.
Source: Clinical and Applied Thrombosis/Hemostasis - September 15, 2013 Category: Hematology Authors: Mahan, C. E., Spyropoulos, A. C., Fisher, M. D., Fields, L. E., Mills, R. M., Stephenson, J. J., Fu, A.-C., Klaskala, W. Tags: Original Articles Source Type: research

New anticoagulants
Arterial and venous thromboembolism are a major health problem and a leading preventable cause of morbidity and mortality. Novel – oral – anticoagulants (NOACs) have recently been introduced into the clinical arena after careful evaluation in clinical trials. They constitute a new array of unique, molecular base designed antithrombotic agents with improved pharmacokinetic and pharmacodynamics characteristics. They have the potential of revolutionizing the treatment in our patients but at the same time important practical issues deserve our attention. This volume, written by international experts from Europe as well as ...
Source: Best Practice and Research. Clinical Haematology - June 1, 2013 Category: Hematology Authors: Menno V. Huisman Source Type: research

Safety and feasibility of transcatheter aortic valve implantation in patients with severe persistent thrombocytopenia
Untreated symptomatic high-grade aortic stenosis remains a lethal disease. Therefore, a comprehensive evaluation is necessary to obtain the best individual treatment for each patient. Recently, transcatheter aortic valve implantation (TAVI) was developed as an innovative therapy for high-risk and inoperable patients. Persistent thrombocytopenia is an established risk for conventional open heart surgery, but is not covered by traditional surgical risk scores. The aim of the study was the investigation of safety and feasibility of TAVI in patients with severe thrombocytopenia. Because of the complicated outcome of patients w...
Source: Blood Coagulation and Fibrinolysis - September 25, 2013 Category: Hematology Tags: Original Articles Source Type: research

Intracerebral Hemorrhage: A Review of Coagulation Function
Intracerebral hemorrhage (ICH) is associated with a higher mortality rate among stroke subtypes. The amount of hematoma at baseline and subsequent expansion are considered strong independent markers for determining poor clinical outcome. Even though reduction in blood pressure to prevent and control the amount of bleeding in ICH has received considerable amount of attention, the impact of coagulopathy and platelet dysfunction, on the bleeding diathesis has not been extensively investigated. With the increasing use of antiplatelets and/or anticoagulants, given the aging population, a deeper understanding of the interactions...
Source: Clinical and Applied Thrombosis/Hemostasis - November 14, 2013 Category: Hematology Authors: Emiru, T., Bershad, E. M., Zantek, N. D., Datta, Y. H., Rao, G. H. R., Hartley, E. W., Divani, A. A. Tags: Original Articles Source Type: research

Oral Anticoagulation Therapy for Elderly Patients With Atrial Fibrillation: Utility of Bleeding Risk Covariates to Better Understand and Moderate Risks
Elderly individuals are prone to nonvalvular atrial fibrillation (AF) with associated risks of arterial thromboembolic disease. Despite definitive guidelines, oral anticoagulant therapy (OAC) is notoriously underutilized in patients with AF. Physicians cite excessive bleeding risk as one reason they omit OAC for their older patients with AF. Improved understanding of the pathophysiology of age-related bleeding may improve risk–benefit assessments for warfarin and newer antithrombotic agents. We reviewed the literature to identify age-related pathophysiological elements that can exacerbate the likelihood of bleeding. ...
Source: Clinical and Applied Thrombosis/Hemostasis - December 12, 2013 Category: Hematology Authors: Forman, D. E., Goyette, R. E. Tags: Original Articles Source Type: research

Resolution of left atrial appendage thrombus with apixaban
In this study, soluble fibrin and D-dimer levels decreased without prolongation of international normalized ratio (INR) and activated partial thromboplastin time (APTT).
Source: Thrombosis Journal - December 20, 2013 Category: Hematology Authors: Tohru KawakamiHiroko KobayakawaHiroyoshi OhnoNobukiyo TanakaHiroki Ishihara Source Type: research

Vitamin K Antagonists: Beyond Bleeding
Abstract Warfarin is the most widely used oral anticoagulant in clinical use today. Indications range from prosthetic valve replacement to recurrent thromboembolic events due to antiphospholipid syndrome. In hemodialysis (HD) patients, warfarin use is even more frequent than in the nonrenal population due to increased cardiovascular comorbidities. The use of warfarin in dialysis patients with atrial fibrillation requires particular caution because side effects may outweigh the assumed benefit of reduced stroke rates. Besides increased bleeding risk, coumarins exert side effects which are not in the focus of clinical routin...
Source: Seminars In Dialysis - January 9, 2014 Category: Hematology Authors: Thilo Krüger, Jürgen Floege Tags: Review Source Type: research

New oral anticoagulant agents - general features and outcomes in subsets of patients.
Abstract During the past four years the phase III trials on stroke prophylaxis in atrial fibrillation and in treatment of venous thromboembolism have been completed for four new oral anticoagulants - dabigatran, apixaban, edoxaban and rivaroxaban. The studies have revealed advantages in terms of a reduced risk of bleeding, most importantly of intracranial bleeding. These anticoagulants also have favourable pharmacokinetics, eliminating the need for routine laboratory monitoring and dose adjustments. There are, however, some differences between the drugs in certain subsets of patients, according to patient characte...
Source: Thrombosis and Haemostasis - January 23, 2014 Category: Hematology Authors: Schulman S Tags: Thromb Haemost Source Type: research

CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention
Conclusions: High CHA2DS2-VASc score was the best predictor of thrombotic outcomes after PCI in a high risk AF population. High mHAS-BLED score was not predictive of bleeding events. More accurate, simple risk scores are needed.
Source: Thrombosis Research - January 24, 2014 Category: Hematology Authors: Marja K. Puurunen, Tuomas Kiviniemi, Axel Schlitt, Andrea Rubboli, Britta Dietrich, Pasi Karjalainen, Kai Nyman, Matti Niemelä, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Clinical Studies Source Type: research

It's not about sex
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 15, 2014 Category: Hematology Authors: M. Greaves Tags: Commentary Source Type: research

Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy - ISAR-CAUTION.
In conclusion, tapered discontinuation of chronic clopidogrel therapy is not superior to abrupt discontinuation regarding the primary endpoint in this study. However, the results must be interpreted in view of the premature termination of the trial and low event rates. PMID: 24633406 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 13, 2014 Category: Hematology Authors: Fiedler KA, Mehilli J, Kufner S, Schlichting A, Ibrahim T, Sibbing D, Ott I, Schunkert H, Laugwitz KL, Kastrati A, Schulz S Tags: Thromb Haemost Source Type: research

It's not about sex.
This article is protected by copyright. All rights reserved. PMID: 24628770 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - March 15, 2014 Category: Hematology Authors: Greaves M Tags: J Thromb Haemost Source Type: research